Hijacking erythropoietin: A tumour-intrinsic strategy to escape immune surveillance

References

[1] Gajewski TF, Meng Y, Blank C, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006; 213: 131-145.

[2] Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313(5795): 1960-1964.

[3] Pages F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018; 391(10135): 2128-2139.

[4] Antoniotti C, Rossini D, Pietrantonio F, et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2022; 23(7): 876-887.

[5] Yuen VW, Chiu DK, Law CT, et al. Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses. J Hepatol. 2023; 78(2): 376-389.

[6] Chiu DK, Zhang X, Cheng BY, et al. Tumor-derived erythropoietin acts as an immunosuppressive switch in cancer immunity. Science. 2025; 388(6745): eadr3026.

[7] Debeljak N, Solar P, Sytkowski AJ, Erythropoietin and cancer: the unintended consequences of anemia correction. Front Immunol. 2014; 5: 563.

[8] Luo B, Gan W, Liu Z, et al. erythropoeitin signaling in macrophages promotes dying cell clearance and immune tolerance. Immunity. 2016; 44(2): 287-302.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.